Asset Details
Do you wish to reserve the book?
Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid
Do you wish to request the book?
Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid
2024
Overview
Detection of peritoneal dissemination (PD) in gastric cancer (GC) patients remains challenging. The feasibility of tumor-guided cell-free DNA (cfDNA) detection in prospectively collected peritoneal fluid (ascites and peritoneal lavage) was investigated and compared to conventional cytology in 28 patients. Besides conventional cytology, next generation sequencing was performed on primary tumor DNA and cell-free DNA from peritoneal fluid. Patients were retrospectively grouped into: a
positive group
(with PD) and a
negative group
(without PD). Detectable mutations were found in the primary tumor of 68% (
n
= 19). Sensitivity of PD detection by tumor-guided cfDNA analysis was 91%, compared to 64% by conventional cytology. Within the positive group (
n
= 11), tumor-guided cfDNA was detected in all patients with ascites samples (4/4, 100%) and in 86% (6/7) of the lavage samples, opposed to 4/4 (100%) patients with ascites and 43% (3/7) with lavage by conventional cytology. Within the negative group (
n
= 8), conventional cytology was negative for all samples. In two patients, tumor-guided cfDNA was detected in peritoneal lavage fluid. Interestingly, these 2 patients developed PD within 6 months, suggesting a prognostic value of tumor-guided cfDNA detection. This study showed that tumor-guided cfDNA detection in peritoneal fluids of GC patients is feasible and superior to conventional cytology in detecting PD.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 45/23
/ Adult
/ Aged
/ Ascites
/ Biomarkers, Tumor - genetics
/ Cell-Free Nucleic Acids - genetics
/ Circulating Tumor DNA - genetics
/ Cytology
/ DNA
/ Female
/ High-Throughput Nucleotide Sequencing - methods
/ Humans
/ Lavage
/ Male
/ Medicine
/ Mutation
/ Oncology
/ Peritoneal Neoplasms - diagnosis
/ Peritoneal Neoplasms - genetics
/ Peritoneal Neoplasms - secondary
/ Stomach Neoplasms - diagnosis
/ Stomach Neoplasms - genetics
/ Stomach Neoplasms - pathology
/ Tumors
